These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19217524)

  • 1. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
    Ogawa K; Kawashima H; Shiba K; Washiyama K; Yoshimoto M; Kiyono Y; Ueda M; Mori H; Saji H
    Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent.
    Ogawa K; Takai K; Kanbara H; Kiwada T; Kitamura Y; Shiba K; Odani A
    Nucl Med Biol; 2011 Jul; 38(5):631-6. PubMed ID: 21718937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
    Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
    Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation.
    Ogawa K; Mukai T; Arano Y; Otaka A; Ueda M; Uehara T; Magata Y; Hashimoto K; Saji H
    Nucl Med Biol; 2006 May; 33(4):513-20. PubMed ID: 16720243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntheses and evaluation of
    Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A
    Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent.
    Ogawa K; Mukai T; Inoue Y; Ono M; Saji H
    J Nucl Med; 2006 Dec; 47(12):2042-7. PubMed ID: 17138748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
    Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
    J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
    Abbasi IA
    Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
    Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
    Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).
    Wunderlich G; Schiller E; Bergmann R; Pietzsch HJ
    Nucl Med Biol; 2010 Nov; 37(8):861-7. PubMed ID: 21055615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro evaluation of
    Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
    Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
    Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
    Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of radiopharmaceuticals for diagnosis and therapy of metastatic bone cancer].
    Ogawa K
    Yakugaku Zasshi; 2012; 132(10):1151-7. PubMed ID: 23037700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of carrier added and no carrier added 90Y-EDTMP as bone seeking therapeutic radiopharmaceutical.
    Khalid M; Bokhari TH; Ahmad M; Bhatti HN; Iqbal M; Ghaffar A; Qadir MI
    Pak J Pharm Sci; 2014 Jul; 27(4):813-8. PubMed ID: 25015445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
    Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
    Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
    Liu CB; Liu GZ; Liu N; Zhang YM; He J; Rusckowski M; Hnatowich DJ
    Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability.
    Mukai T; Suwada J; Sano K; Okada M; Yamamoto F; Maeda M
    Bioorg Med Chem; 2009 Jul; 17(13):4285-9. PubMed ID: 19481944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.